Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.

Automated summary

This clinical trial investigated the risk of disease activity flares in rheumatoid arthritis patients who discontinued csDMARDs compared to those who continued with half-dose csDMARDs. The trial was open-label and randomized, and the follow-up period was 12 months.